{"id":13993,"date":"2011-07-15T10:30:00","date_gmt":"2011-07-15T08:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/fusioni-e-acquisizioni-in-aumento-negli-usa\/"},"modified":"2011-07-15T10:30:00","modified_gmt":"2011-07-15T08:30:00","slug":"fusioni-e-acquisizioni-in-aumento-negli-usa","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/fusioni-e-acquisizioni-in-aumento-negli-usa\/","title":{"rendered":"Mergers and acquisitions on the rise in the US"},"content":{"rendered":"

American pharmaceutical companies plan to step up their mergers and acquisitions in an effort to appropriate new therapies. And they have the money to do it, according to a survey conducted overseas by KPMG. <\/p>\n

<\/font><\/font><\/span><\/p>\n

100 US pharmaceutical executives were interviewed and the 83% said their company is likely to be involved in a merger or acquisition as a buyer or seller in the next two years. Furthermore, approximately 41% of respondents believe that the largest area of spending in the coming year will be acquisitions, followed by new products and services, at 38%, and research and development, also at 38%. <\/p>\n

<\/font><\/font><\/span><\/p>\n

A strategic acquisition was cited as the top investment priority by 40% executives, followed by expansion into new markets (22%). The 58% identifies patent expirations and generic competition as the key issues facing your business. This is followed by increasing demands from regulatory authorities (45%) and a lack of new products in the pipeline (34%). More than three-quarters said companies have significant cash availability and half expect an increase over the next year. But how soon will companies fully recover? According to executives 31% by the end of next year, for 27% not before the end of 2013 and for 27% at the end of 2014.<\/p>\n

<\/font><\/font><\/span><\/p>\n

Barbara Di Chiara \u2013 15 July 2011 \u2013 Pharmakronos <\/span><\/em><\/p>\n

\"\"<\/em><\/p>","protected":false},"excerpt":{"rendered":"

Le aziende farmaceutiche americane hanno intenzione di intensificare la loro attività di fusioni e acquisizioni, nel tentativo di appropriarsi di nuove terapie. E hanno il denaro per farlo, secondo un sondaggio condotto Oltreoceano dalla Kpmg. Sono stati intervistati 100 dirigenti del settore farmaceutico statunitense e l’83% ha affermato che è probabile che la loro società …<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-13993","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/13993","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=13993"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/13993\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=13993"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=13993"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=13993"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}